

AS01[®]-like Adjuvant Systems - Development and Commercialization

Valens[™] T4Q: development toward an AS01-like adjuvant system

SPI Pharma is partnered with Inimmune Corp to commercialize an AS01-like adjuvant system.



The T4Q adjuvant system is an AS01-like adjuvant system combining Inimmune's novel synthetic TLR4 agonist INI-2002 with saponin adjuvants from SPI Pharma. SPI Pharma saponins and combinations with INI-2002 offer advantages over current clinical adjuvants. Some of those advantages include improved availability, stability, and production sustainability. INI-2002 alone offers greatly improved stability compared to current clinical TLR4 adjuvants. Additionally, we have developed an innovative formulation approach that avoids the cold chain requirement of current clinical TLR4 + saponin adjuvant combinations.

In July 2024, SPI Pharma and Inimmune Corp announced a partnership to develop and commercialize this adjuvant system.

Efficacy in Pre-Clinical Models

- T4Q demonstrates comparable or improved immunogenicity compared to current clinical TLR4 + saponin adjuvant combinations
- Corresponding or improved injection site pain compared to current clinical TLR4 + saponin adjuvant combinations depending on the formulation of T4Q that is being investigated.
- T4Q adjuvanted vaccines are efficacious in pre-clinical influenza challenge models.

cGMP Manufacturing

- INI-2002 has been manufactured under cGMP conditions
- Our partners have either completed cGMP manufacturing of saponin alternatives or cGMP manufacturing campaigns are underway.
- T4Q cGMP manufacturing is in progress with completion expected Q1 2025.

SPI Pharma, as the commercial partner, can assist you with Inimmune's expertise to help develop vaccines readily and easily from our T4Q platform. Please contact SPI Pharma to discuss your needs further, including T4Q samples and relevant data.

www.spipharma.com • salesinfo@spipharma.com



All information and statements given in this brochure are believed to be accurate at the time of publication. However, neither SPI Pharma nor any of their affiliates make any representations or warranty with respect thereto, including, but not limit to, any results obtained in the processing of the products by customers or any third party. All information and statements are intended for persons having the required skill and know-how and do not relieve the customer or user from verifying the suitability of information and statements given for a specific purpose prior to use of products. It is entirely the obligation of the customer or user to comply with applicable laws and regulations, and also with all patent or other intellectual property rights of third parties.

AS01 is a registered trademark of GSK Biologicals S.A.